OVARIAN CANCER

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was still found during a second-look surgery. About 35 adults with advanced-stage cancer who already had standard chemotherapy and surgery will rece…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (like ovarian, breast, prostate, and lung cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and tolerable when given alon…

This early-phase study tests an investigational cell therapy called P-MUC1C-ALLO1 in adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for early sign…

This study tests a personalized immunotherapy called Vigil in 92 people with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses a patient's own tumor cells to train their immune system to fight any remaining cancer cells. The …

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It involved 162 adults whose cancer had responded to platinum-based treatment before.…

This study tests a drug called IMP4297 (a PARP inhibitor) as a long-term maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this pill daily can delay the cancer from ret…

This study planned to test a combination of two drugs, bemarituzumab and bevacizumab, in people with advanced or metastatic endometrial, ovarian, or cervical cancers that have a specific protein (FGFR2b). The goal was to find the safest dose and see if the combination could shrin…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell ovarian, fallopian tube, or peritoneal cancer. About 46 participants will receive either one or both drugs to see if …

This study tests whether combining a cancer vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine trains the immune system to attack …

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer who have responded well to chemotherapy. The goal is to see if taking this pill daily can delay the cancer from coming back. The trial involves 224 participants …

This early-stage study tests two drugs, niraparib and neratinib, together in people with advanced solid tumors or ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find the safest dose and see if the combination can stop the cancer from growing for a…

This early-phase study tests a personalized cell therapy for people with certain advanced cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, sarcoma) that carry a protein called MAGE-A4. Patients' own immune cells are genetically modified to recognize and …

This study tested a combination of three drugs (nivolumab, bevacizumab, and rucaparib) in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the combination could shrink tumors or slow cancer growth. While t…

This study looks at the best time for surgery in people with advanced ovarian cancer. It compares having surgery right away versus having chemotherapy first and then surgery. The goal is to see which approach helps people live longer. About 800 participants took part in this tria…

This phase 2 study tests a personalized cell therapy (ADP-A2M4CD8) alone or with another drug (nivolumab) in 66 people with recurrent ovarian cancer. Only patients with certain genetic markers (HLA-A*02 and MAGE-A4) can join. The goal is to see if the treatment shrinks tumors and…

This early-phase study tests a treatment called TBI-1301 for people with advanced solid tumors (like sarcoma, melanoma, or ovarian cancer) that have not responded to other therapies. The treatment uses a patient's own immune cells, which are genetically modified in a lab to bette…

This early-phase study tests a new oral drug, MOMA-313, alone or with another drug (olaparib) in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study tests a new drug called PF-07104091 in people with advanced small cell lung, ovarian, or breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug can shrink tumors when used alone or with other cancer medicines…

This study tests whether a new drug (ONC-392) combined with an existing immunotherapy (pembrolizumab) can shrink tumors or slow disease in people with ovarian cancer that no longer responds to platinum chemotherapy. About 58 adults with high-grade serous ovarian, primary peritone…

This study tests a new drug, BT5528, given alone or with another drug (nivolumab) in people with advanced solid tumors that have high levels of a protein called EphA2. The main goals are to find safe doses and learn about side effects. The study also checks if the drug can shrink…

This study tests a new combination of three drugs (ALX148, liposomal doxorubicin, and pembrolizumab) in 16 people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and improve survival. Pa…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before surgery. The main goa…

This study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has come back after prior treatment. The goal is to see if the drugs can shrink or control the tumors. Participants must have a specific KRAS ge…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian cancer live longer without the disease coming back. About 362 participants will either get standard surgery alone or surgery plus the heated chemo. The …

This early-stage trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after prior therapy. The treatment is given directly into the abdomen three times in one week, after a short course of chemotherapy to…

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This study tests whether combining two drugs (atezolizumab and tivozanib) can help the immune system attack cancers that usually don't respond to immunotherapy, like certain prostate, pancreatic, and breast cancers. About 29 adults with advanced or metastatic disease who have alr…

This study tests two new drug combinations for people with a type of ovarian cancer that has stopped responding to a standard treatment called PARP inhibitors. The trial involves 63 participants and aims to see if the new combinations can shrink or control the tumor. The goal is …

This study offers continued treatment with avelumab to cancer patients who are already benefiting from it in earlier Pfizer studies. It includes safety monitoring and survival follow-up for people with advanced cancers like lung, ovarian, and bladder cancer. The goal is to keep p…

This early-phase trial tests a treatment for adults with certain advanced solid tumors (like colorectal, lung, or breast cancer) that have spread and stopped responding to standard therapy. The approach uses a person's own white blood cells, which are genetically modified in a la…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 366 women with a specific type of ovarian cancer that does not have a BRCA gene mutation will receive either olaparib or a placebo daily. The goal i…

This early-phase study tests a new treatment called T-Plex for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack multiple cancer-related targets. Th…

This study offers continued access to the drug olaparib for people with ovarian or breast cancer who were already taking it in a previous study and are still benefiting. The goal is to keep providing the treatment while monitoring for serious side effects. About 185 participants …

This study tests several new drugs chosen based on the unique markers of each person's rare ovarian cancer. It includes 176 adults whose cancer has persisted or returned after standard treatment. The goal is to see if these targeted therapies can shrink tumors or slow the disease…

This early-stage trial tests a new treatment for ovarian cancer using specially engineered immune cells (called OC-EIEs) designed to recognize and attack cancer cells. About 20 women with advanced ovarian cancer will receive the cells to see if it is safe and shrinks tumors. The …

This study tests whether a combination of three drugs (olaparib, durvalumab, and UV1) can help keep ovarian cancer from coming back in people whose tumors do not have a BRCA gene mutation. About 188 participants with recurrent ovarian cancer will receive this combination as maint…

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This early-phase study tests two experimental immunotherapy drugs (botensilimab and balstilimab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 499 participants with various can…

This study tests a drug called CYH33 in people whose ovarian, fallopian tube, or peritoneal clear cell cancer has come back or not gone away. It is for those with a specific gene change (PIK3CA mutation) and who have already tried standard chemotherapy. The main goal is to see if…

This study looks at whether adding Juice Plus+ and Juice Plus+ Complete supplements to the diet helps ovarian cancer patients who are in remission. About 75 participants will either take the supplements or receive dietary counseling alone. Researchers will measure changes in bloo…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian tube, or …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants are randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to see if…

This is a first-in-human study to test the safety and find the right dose of an experimental pill called ATV-1601. It is for adults with advanced solid tumors, including certain breast, gynecologic, and prostate cancers, that have a specific genetic change called an AKT1 E17K mut…

This study is testing whether a special MRI contrast agent, called hyperpolarized 13-C pyruvate, can help doctors see how aggressive ovarian cancer is. About 30 people at high risk for ovarian cancer will take part. The main goal is to check safety and see if the imaging works on…

This study is testing whether a simple saliva sample can help doctors tell if an ovarian mass is cancerous, borderline, or benign. Researchers are analyzing RNA molecules in saliva from 746 women scheduled for surgery. The goal is to create a faster, non-invasive diagnostic tool …

This study looks at whether removing the fallopian tubes at the same time as a hysterectomy (for non-cancer reasons) can lower the chance of getting ovarian cancer later. About 4,400 women under 55 will take part, and researchers will check for complications, effects on menopause…

This study tests a program called Journey Ahead that helps women with gynecologic cancers (like ovarian, endometrial, or cervical cancer) improve their coping and communication skills. About 30 women who have been diagnosed or had a recurrence in the past 5 years will take part. …

This study compares two ways of giving high-dose radiation to people with cancer that has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls the cancer in t…

This study looks at a fast way to identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It also compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active treatment took part. T…

This study tests whether a group-based web program can improve quality of life and reduce stress in ovarian cancer survivors. About 326 survivors will take part, comparing a mindfulness program to a healthy lifestyle program. The goal is to see if these online tools help with str…

This study gathers information from 240 women who have lived with ovarian cancer for at least seven years. Researchers want to learn how diet, exercise, emotions, and social support affect their long-term survival. No new treatments are tested; the goal is simply to understand wh…

This study aims to create a repository of biological samples—such as blood, urine, and tumor tissue—from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. Researchers will use these samples to study DNA changes that drive cancer, which may guide fu…

This study interviews 24 women aged 25 and older who have a BRCA1 or BRCA2 mutation to learn how they might use polygenic risk scores and new early detection tests when deciding about cancer screening or preventive surgery. The goal is to better understand patient attitudes, not …

This study explores a new way to predict how ovarian cancer will respond to chemotherapy. Researchers take thin slices of a patient's tumor and test different drugs on them in the lab. The goal is to see if this method can accurately forecast which treatment will work best for ea…

This study collects DNA from over 21,000 people with different cancers (like breast, colon, and lung) in New York. Researchers will look for inherited gene changes that might be linked to cancer. The goal is to find clues for future studies, not to test a treatment.

This study looks at how diet, lifestyle, and genetics influence the risk of getting endometrial cancer. Researchers will compare women who have or had the cancer with those who do not. The goal is to identify factors that may lead to the disease. About 1,315 women from New Jersey…

This study tests whether a reminder sent to doctors can increase the number of women with suspicious ovarian masses who are referred to a gynecologic oncologist within 30 days. The study includes 20 women aged 18 and older with a suspicious mass found on imaging. Researchers will…

This study looks at whether a blood test that finds tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after surgery for early ovarian cancer. Researchers will test stored blood samples from 50 patients taken before and after surgery. The goal…

This study looks at 100 women with breast or gynecological cancer to see if their diet before starting chemotherapy affects levels of a protein called hepcidin. Researchers want to know if hepcidin levels are linked to how much of the planned chemotherapy dose patients actually r…

This study looks at a new approach where cancer doctors offer genetic testing directly to patients with ovarian, prostate, or pancreas cancer, instead of referring them to a genetic counselor. The goal is to see how patients feel about this method and if it changes their distress…

This study involves 10 people with advanced ovarian cancer who have finished their first round of chemotherapy. Researchers use a second look laparoscopy to check for small amounts of leftover cancer cells. They want to see how these findings relate to long-term health outcomes a…

This study looks at the 'time toxicity' of cancer—how much time people with advanced breast or ovarian cancer spend on care tasks like appointments, travel, and managing symptoms. About 80 participants will use a smartphone app for 28 days to track their activities and daily well…

This study looks at whether combining PET/MRI scans with blood and tissue tests can create a detailed profile of high-grade serous ovarian cancer. The goal is to better predict how tumors respond to treatment, which could help doctors personalize care. About 10 participants with …

This study is testing a new genetic test (called Gersom panel) in 4,000 people with breast, ovarian, or colorectal cancer. The goal is to see if the test can accurately find inherited genetic risks and tumor mutations that might guide treatment choices. Participants provide blood…

This study aims to find genetic and protein changes in ovarian, endometrial, and cervical cancers. Researchers will analyze tissue samples from 300 adults suspected of having these cancers. The goal is to link these molecular changes to patient outcomes, which may help guide futu…

This pilot study tested whether a prehabilitation program—a set of exercises and health support before surgery—is practical and helpful for 22 women with advanced ovarian cancer. Participants received the program while undergoing chemotherapy to prepare for tumor-removal surgery.…

This study tests whether a blood test (liquid biopsy) can be used instead of multiple tissue samples to see how ovarian cancer changes over time. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to 2 years. The goal is to see if the…